{"entity":{"id":"nice","kind":"institution","name":"National Institute for Health and Care Excellence","aka":["NICE"],"tldr":"England's health technology assessment body, which decides whether the NHS should pay for each new cancer drug on cost per quality-adjusted life year and runs the Cancer Drugs Fund.","summary":"Established in 1999, NICE appraises new medicines for the NHS in England (and by adoption Wales and Northern Ireland) and issues clinical guidelines and quality standards. Its technology appraisals judge cost-effectiveness against a threshold of £25,000 to £35,000 per QALY, raised from £20,000 to £30,000 by a government direction that took effect on 2 April 2026, with a higher weight for severe conditions, and its decisions determine whether patients in England can access new cancer drugs on the NHS. The Cancer Drugs Fund, reformed in 2016, provides managed access to promising drugs while further evidence is collected, and NICE has pioneered the use of real-world data from the fund in re-appraisal. NICE guidance is influential in HTA globally, and it partners with the MHRA on the Innovative Licensing and Access Pathway.","asOf":"2026-09-09","links":[{"label":"NICE","url":"https://www.nice.org.uk"},{"label":"Cancer guidance","url":"https://www.nice.org.uk/guidance/conditions-and-diseases/cancer"}],"tags":[],"related":["nice-guidance","src-nice-ta"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["mhra","smc","cruk","macmillan-cancer-support","ema","royal-marsden"],"pathways":[],"terms":["real-world-evidence","os","pfs","hazard-ratio"],"trials":[],"people":["jonathan-benger"],"bottlenecks":["b-drug-pricing","b-real-world-evidence","b-global-access"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"London","country":"GB","lat":51.521,"lng":-0.083,"institutionType":"government","website":"https://www.nice.org.uk","programs":["Technology appraisals (cost per QALY)","Cancer Drugs Fund managed access","Clinical guidelines (NG series)","Innovative Licensing and Access Pathway"]},"route":"/institutions/nice/","neighbours":{"collection":[{"id":"nice-guidance","kind":"collection","name":"NICE cancer guidance and technology appraisals (UK)","route":"/collections/nice-guidance/"},{"id":"src-nice-ta","kind":"collection","name":"NICE technology appraisals","route":"/collections/src-nice-ta/"}],"institution":[{"id":"bfarm","kind":"institution","name":"Bundesinstitut für Arzneimittel und Medizinprodukte","route":"/institutions/bfarm/"},{"id":"cruk","kind":"institution","name":"Cancer Research UK","route":"/institutions/cruk/"},{"id":"ema","kind":"institution","name":"European Medicines Agency","route":"/institutions/ema/"},{"id":"g-ba-iqwig","kind":"institution","name":"Gemeinsamer Bundesausschuss / IQWiG","route":"/institutions/g-ba-iqwig/"},{"id":"has-france","kind":"institution","name":"Haute Autorité de Santé","route":"/institutions/has-france/"},{"id":"ispor","kind":"institution","name":"ISPOR (The Professional Society for Health Economics and Outcomes Research)","route":"/institutions/ispor/"},{"id":"macmillan-cancer-support","kind":"institution","name":"Macmillan Cancer Support","route":"/institutions/macmillan-cancer-support/"},{"id":"mhra","kind":"institution","name":"Medicines and Healthcare products Regulatory Agency","route":"/institutions/mhra/"},{"id":"nhsa","kind":"institution","name":"National Healthcare Security Administration","route":"/institutions/nhsa/"},{"id":"pbac","kind":"institution","name":"Pharmaceutical Benefits Advisory Committee","route":"/institutions/pbac/"},{"id":"smc","kind":"institution","name":"Scottish Medicines Consortium","route":"/institutions/smc/"},{"id":"royal-marsden","kind":"institution","name":"The Royal Marsden","route":"/institutions/royal-marsden/"}],"term":[{"id":"cancer-drugs-fund","kind":"term","name":"Cancer Drugs Fund (England)","route":"/terms/cancer-drugs-fund/"},{"id":"hazard-ratio","kind":"term","name":"Hazard ratio (HR)","route":"/terms/hazard-ratio/"},{"id":"ilap","kind":"term","name":"ILAP (Innovative Licensing and Access Pathway)","route":"/terms/ilap/"},{"id":"innovative-medicines-fund","kind":"term","name":"Innovative Medicines Fund (England)","route":"/terms/innovative-medicines-fund/"},{"id":"nice-methods","kind":"term","name":"NICE technology appraisal methods (2022)","route":"/terms/nice-methods/"},{"id":"os","kind":"term","name":"Overall survival (OS)","route":"/terms/os/"},{"id":"pancreatic-cancer-uk-drug-access","kind":"term","name":"Pancreatic cancer drugs in England: NICE appraisals and the Cancer Drugs Fund (September 2026)","route":"/terms/pancreatic-cancer-uk-drug-access/"},{"id":"pfs","kind":"term","name":"Progression-free survival (PFS)","route":"/terms/pfs/"},{"id":"real-world-evidence","kind":"term","name":"Real-world evidence","route":"/terms/real-world-evidence/"}],"person":[{"id":"jonathan-benger","kind":"person","name":"Jonathan Benger","route":"/people/jonathan-benger/"}],"bottleneck":[{"id":"b-global-access","kind":"bottleneck","name":"Most of the world has almost no cancer care","route":"/bottlenecks/b-global-access/"},{"id":"b-drug-pricing","kind":"bottleneck","name":"Prices and value","route":"/bottlenecks/b-drug-pricing/"},{"id":"b-real-world-evidence","kind":"bottleneck","name":"Weak real-world evidence and registries","route":"/bottlenecks/b-real-world-evidence/"}],"cancer":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"idea":[{"id":"idea-tnbc-uk-trial-access-and-germline-testing-audit","kind":"idea","name":"A UK audit of trial access and germline testing uptake in triple-negative breast cancer","route":"/ideas/idea-tnbc-uk-trial-access-and-germline-testing-audit/"},{"id":"idea-cost-managed-access-everywhere","kind":"idea","name":"Copy the Cancer Drugs Fund: pay for uncertain drugs while collecting the data","route":"/ideas/idea-cost-managed-access-everywhere/"},{"id":"idea-tnbc-pd-l1-assay-harmonisation","kind":"idea","name":"Harmonise PD-L1 testing for triple-negative breast cancer around one scored assay, with external quality assurance","route":"/ideas/idea-tnbc-pd-l1-assay-harmonisation/"},{"id":"idea-lung-uk-screening-testing-and-access-gaps","kind":"idea","name":"Publish the four numbers the NHS lung cancer pathway does not currently measure: reflex testing rate, genomic turnaround, surgical access and a lung-specific waiting time in every nation","route":"/ideas/idea-lung-uk-screening-testing-and-access-gaps/"},{"id":"idea-crc-uk-colonoscopy-capacity-and-fit-threshold","kind":"idea","name":"UK gap: match endoscopy capacity and quality to the faecal immunochemical test thresholds the NHS has already set","route":"/ideas/idea-crc-uk-colonoscopy-capacity-and-fit-threshold/"},{"id":"idea-crc-uk-young-patient-referral-and-diagnostic-interval","kind":"idea","name":"UK gap: shorten the route to diagnosis for patients below the screening age, where the rise in incidence is","route":"/ideas/idea-crc-uk-young-patient-referral-and-diagnostic-interval/"}],"paper":[{"id":"paper-atkin-flexible-sigmoidoscopy-17-year-follow-up-lancet-2017","kind":"paper","name":"Long term effects of once-only flexible sigmoidoscopy screening after 17 years of follow-up","route":"/key-papers/paper-atkin-flexible-sigmoidoscopy-17-year-follow-up-lancet-2017/"}],"roadmap":[{"id":"colorectal-roadmap","kind":"roadmap","name":"Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation","route":"/roadmaps/colorectal-roadmap/"},{"id":"lymphoma-roadmap","kind":"roadmap","name":"Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting","route":"/roadmaps/lymphoma-roadmap/"}],"technology":[{"id":"homeopathy-cancer","kind":"technology","name":"Homeopathy","route":"/technologies/homeopathy-cancer/"}]}}